Spots Global Cancer Trial Database for recurrent head and neck cancer
Every month we try and update this database with for recurrent head and neck cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer | NCT01255800 | Recurrent Head ... | IPI-926 and Cet... | 18 Years - | University of Colorado, Denver | |
| Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract | NCT04673929 | Recurrent Head ... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Lapatinib and Cetuximab in Patients With Solid Tumors | NCT01184482 | Colorectal Canc... Lung Cancer Head and Neck C... | cetuximab and l... | 18 Years - | Georgetown University | |
| Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00003489 | Head and Neck C... | Antineoplaston ... | 16 Years - 99 Years | Burzynski Research Institute | |
| A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | NCT02358031 | Recurrent Head ... Metastatic Head... | Pembrolizumab Cisplatin Carboplatin 5-FU Cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study | NCT05738187 | Recurrent Head ... Local Cryothera... | local cryothera... | 18 Years - | University Hospital, Strasbourg, France | |
| Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | NCT05980000 | Recurrent Head ... Recurrent Head ... Recurrent Head ... Metastatic Head... Metastatic Head... HNSCC | Ramucirumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00003489 | Head and Neck C... | Antineoplaston ... | 16 Years - 99 Years | Burzynski Research Institute | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | NCT01606566 | Recurrent Head ... Carcinoma, Squa... | Amphinex induce... | 18 Years - | PCI Biotech AS | |
| Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study | NCT05738187 | Recurrent Head ... Local Cryothera... | local cryothera... | 18 Years - | University Hospital, Strasbourg, France | |
| Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients | NCT01172470 | Head and Neck C... | Gemcitabine Pemetrexed Carboplatin | 18 Years - | University of Chicago | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | NCT02289209 | Recurrent Head ... Carcinoma, Squa... | Reirradiation MK-3475 | 18 Years - | University of Pittsburgh | |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | NCT04260126 | Metastatic Head... Recurrent Head ... HPV Positive Or... Neoplasms, Head... | Pembrolizumab (... | 18 Years - | PDS Biotechnology Corp. | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer | NCT03937141 | Metastatic Head... Recurrent Head ... | ADU-S100 | 18 Years - | Chinook Therapeutics, Inc. | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients | NCT01172470 | Head and Neck C... | Gemcitabine Pemetrexed Carboplatin | 18 Years - | University of Chicago | |
| Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | NCT00620295 | Breast Cancer Colorectal Canc... Head and Neck C... Kidney Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer Sarcoma | bortezomib gemcitabine hyd... | 70 Years - | Masonic Cancer Center, University of Minnesota | |
| PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | NCT06239220 | Head and Neck C... Head and Neck S... Metastatic Head... Recurrent Head ... Metastatic Head... Recurrent Head ... | PD-L1 t-haNK Cetuximab N-803 | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | NCT00622674 | Breast Cancer Colorectal Canc... Head and Neck C... Kidney Cancer Lung Cancer Pancreatic Canc... Sarcoma Unspecified Adu... | cetuximab bortezomib | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study | NCT05738187 | Recurrent Head ... Local Cryothera... | local cryothera... | 18 Years - | University Hospital, Strasbourg, France | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers | NCT04902027 | Recurrent Head ... Metastatic Head... | Mitoxantrone Hy... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract | NCT04673929 | Recurrent Head ... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | NCT00620295 | Breast Cancer Colorectal Canc... Head and Neck C... Kidney Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer Sarcoma | bortezomib gemcitabine hyd... | 70 Years - | Masonic Cancer Center, University of Minnesota | |
| Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer | NCT00088907 | Recurrent Head ... Metastatic Head... | docetaxel placebo gefitinib | 18 Years - | National Cancer Institute (NCI) | |
| Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer | NCT02567383 | Recurrent Head ... | Radiation Hyperthermia; T... Cisplatin Taxotere | 20 Years - 85 Years | Shin Kong Wu Ho-Su Memorial Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
